Navigation Links
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Date:9/4/2007

Results Further Validate Lipidomic-Based Therapeutics as an Emerging Area

of Drug Discovery

SAN DIEGO, Sept. 4 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported positive results in several murine models of human cancer and AMD with Lpathomab(TM), the company's mouse monoclonal antibody against LPA (lysophosphatidic acid). These results confirm the expected potent anti-angiogenic and anti-metastatic actions of Lpathomab. Lpathomab was created using Lpath's proprietary ImmuneY2(TM) platform technology.

Based on this positive outcome, Lpath will collaborate with DataMabs of London, England, to humanize Lpathomab to create a lead antibody for pre- clinical development.

LPA is a bioactive lipid long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types, as well as a significant contributor to neuropathic pain.

"Humanizing our Lpathomab antibody is a vital next step in moving the project into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice president of research. "We've had great success in the past working with DataMabs and look forward to working with them again on our Lpathomab project."

This achievement with Lpathomab comes on the heels of Lpath's success with its Sphingomab(TM) program. Sphingomab is an antibody against another bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to file an IND in November of this year for the use of ASONEP(TM) (the systemic formulation of humanized Sphingomab) for the treatment of cancer. It also plans to file a second IND early next year for the use of iSONEP(TM) (the ocular formulation of humanized Sphingomab) for the treatment of AMD. The company plans to submit an IND filing for the use of humanized Lpathomab in 2009.

Dr. Roger Sabbadini, the founder and CSO of Lpath, commented, "These excitin
'/>"/>

SOURCE Lpath, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...FirstCall/--HeskaCorporation(HSKA);("Heska"),alead...ctstotheveterinaryindustry,announcedtodayagreement...dgasproductsandaffiliatedconsumablesfortheveterina...bin/prnh/20000622/HESKALOGO ) ,, "HeskaandRoche...edpoint-of-carediagnostics,"commentedMichaelMcGinl...
(Date:11/25/2009)...TrendsResearchGroup,Inc.releasedWave1ofits Launch...asesyndicatedmarketresearchprojecttrackingthelaunc...hthroughthefirstsixmonthsofavailability.Eachwaveof...ueDermatologistsandqualitativeinformationfromasubs...lestouse,typicalpatienttypes,productperceptions,pr...
(Date:11/25/2009)...re/--RegadoBiosciences,aprivatelyheldcompanyleadin...ontrolagents,announcedthatDavidMazzo,PhD,CEOandPre...HealthCareConferenceattheNewYorkPalaceHotelinNewYo...ST)onTuesday,December1andwillincludeanoverviewofth...program,theanticoagulantsystem,REG1.Thehealthcarei...
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Walking hazard 3A Cell phone use but not music reduces pedestrian safety 61422 1Walking hazard 3A Cell phone use but not music reduces pedestrian safety 61422 2The evolving manager stereotype 3A Gender a factor in measuring a teams performance 61420 17th International Chronic Total Occlusion Summit in New York City 61418 1
... MELBOURNE, Australia, May 03, 2007 /PRNewswire-Fi...nced today that the Company,intends to initiate a ...y and safety of the improved formulation of its tr...ing long-acting insulin.,The trial is expected to ...nsulin gel is being developed as a novel "needle-f...
...CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2007 - X...emonstrating that,Symadex(TM) reversed the clinica...animal model for multiple sclerosis. The presentat...r of Diagnostic,Radiology at the University of Wes...rchers from Xanthus in a poster session at the,59t...
Other Medicine Technology:Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 3
(Date:11/25/2009)...eumatoid arthritis, could help newly diagnosed dia...25 (HealthDay News) -- A drug commonly used to tre... now also shows some promise in helping patients n..., rituximab (Rituxan), helped patients keep produc...ease had destroyed some of their pancreatic beta c...
(Date:11/25/2009)...ical symptoms, study finds , , WEDNESDA...ffects are among the potential problems faced by l...reated with cisplatin-based chemotherapy, a new st...gian men treated for unilateral testicular cancer ... survey conducted from 1998 to 2002. , The rese...
(Date:11/25/2009)...wire-USNewswire/--TheAmericanAssociationforHomecar....2128,whichisdesignedtosubstantiallyimprovetoolsan...lwasintroducedbySen.GeorgeLeMieux(R-Fla.). ,, T...ssociationforHomecareoutlinedinits13-pointanti-fra...inFebruary.Thoseprovisionsincludecallingforreal-ti...
(Date:11/25/2009)...ancer also can reverse a rare stomach disorder and...isease, researchers at Vanderbilt University Medic...auses thickening of the stomach lining, severe abd...a and swelling in the feet and ankles due to prote...c cancer. Previously, the only effective treatment...
(Date:11/25/2009)...hat mimicked parts of speech colored perception of...y News) -- People can "hear" not only with their e... , In fact, sensations on the skin designed to ...le decipher sounds better, the Canadian scientists...her we could use tactile information in this way,"...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3
...est assesses osteoporosis risk and helps provide p...r bone health, CINCINNATI and BRIDGEWATER, N.J., ...tand your risk factors for osteoporosis, using a,n...test asks less than 20 simple questions about fami...
...nsecutive Year in Deloitte,s Technology Fast 50 Pr...stems,Inc. (Nasdaq: CASM ), a medical device comp... monitoring, today announced that it has been name...life sciences companies in the area by Deloitte & ...
...nt to Host Conference Call and Webcast Same Aftern...,BZI), a provider of functional foods, beverages a...he Company will report its financial and,operation...ernoon beginning at,4:15 PM Eastern Time, and invi...
...LIS, Oct. 19 Uroplasty, Inc. (Amex:,UPI) announce... with the,U.S. Securities and Exchange Commission ...10,000,000 (exclusive of over-allotment option) of...ic offering.,A copy of the prospectus relating to ...
...xis to Demonstrate Advanced Coronary & Peripheral ...ping at TCT 2007 Stereotaxis, Mobile Vasc...Stereotaxis, Inc. (Nasdaq:,STXS) announced today t...erapeutics (TCT) symposium in Washington,D.C., Oct...
...UGE, La., Oct. 19 Amedisys, Inc.,(Nasdaq: AMED or...lth,nursing companies, today announced that it int...ter ended September 30, 2007 pre-market on Tuesday...onference call, please dial 800-683-1525,(Domestic...
Other Medicine News:Health News:Sixty Seconds That Can Change Your Life 2Health News:Sixty Seconds That Can Change Your Life 3Health News:Sixty Seconds That Can Change Your Life 4Health News:Sixty Seconds That Can Change Your Life 5Health News:CAS Medical Systems, Inc. Ranked Among Connecticut's Fastest Growing Technology Companies 2Health News:CAS Medical Systems, Inc. Ranked Among Connecticut's Fastest Growing Technology Companies 3Health News:CAS Medical Systems, Inc. Ranked Among Connecticut's Fastest Growing Technology Companies 4Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 3Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 4Health News:Amedisys to Host Conference Call to Discuss Third Quarter Financial Performance and Operating Results 2
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...ge group?, ,Babies and young children have troubl...f an MDI. , ,Dry powder devices require a high mi... , ,Traditional nebulizers have high wastage and ...or this age group are inefficient at delivering me...
...Compressor is for active patients who want to take... The compressor is small and lightweight, yet powe...e AC compatibility (100 to 240V), 12 volt DC and r...o take aerosol treatments away from home, in their...
...Compressor is for active patients who want to take... The compressor is small and lightweight, yet powe...e AC compatibility (100 to 240V), 12 volt DC and r...o take aerosol treatments away from home, in their...
Medicine Products: